{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:24:08Z","timestamp":1791905048065,"version":"4.3.4"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.numecd.2014.05.009","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T06:30:30Z","timestamp":1402036230000},"page":"1057-1066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":199,"title":["Resistance and intolerance to statins"],"prefix":"10.1016","volume":"24","author":[{"given":"\u017d.","family":"Reiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2014.05.009_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11886-012-0313-7","article-title":"Dyslipidemias in the prevention of cardiovascular disease: risks and causality","volume":"14","author":"Graham","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.numecd.2014.05.009_bib2","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2014.05.009_bib3","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","author":"Stone","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrcardio.2013.80","article-title":"Statins in the primary prevention of cardiovascular disease","volume":"10","author":"Reiner","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3325\/cmj.2013.54.339","article-title":"Prevalence and types of persistent dyslipidemia in patients treated with statins","volume":"54","author":"Reiner","year":"2013","journal-title":"Croat Med J"},{"key":"10.1016\/j.numecd.2014.05.009_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.atherosclerosis.2013.09.020","article-title":"EUROASPIRE III study group. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey","volume":"231","author":"Reiner","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2014.05.009_bib7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2014.05.009_bib8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"25","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2014.05.009_bib9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.107.708388","article-title":"Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment","volume":"117","author":"Krauss","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2014.05.009_bib10","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.numecd.2014.05.009_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/sj.tpj.6500328","article-title":"An association study of 43 SNPs in 16 candidate genes with atorvastatin response","volume":"5","author":"Thompson","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.numecd.2014.05.009_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCGENETICS.108.818062","article-title":"Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort","volume":"2","author":"Thompson","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.numecd.2014.05.009_bib13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/FPC.0b013e3283106071","article-title":"A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study","volume":"18","author":"Donnelly","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.numecd.2014.05.009_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2007.12.004","article-title":"Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER","volume":"200","author":"Polisecki","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2014.05.009_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcp.2008.09.019","article-title":"ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment","volume":"77","author":"Rebecchi","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.numecd.2014.05.009_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.amjcard.2004.01.014","article-title":"Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner","volume":"93","author":"Kajinami","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2125.2006.02599.x","article-title":"Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms","volume":"61","author":"Bernsdorf","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.numecd.2014.05.009_bib19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/ATVBAHA.109.188474","article-title":"Identification of genetic variants associated with response to statin therapy","volume":"29","author":"Mega","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2014.05.009_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCGENETICS.108.795013","article-title":"Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response","volume":"1","author":"Voora","year":"2008","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.numecd.2014.05.009_bib21","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/00498254.2011.562566","article-title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins","volume":"41","author":"Generaux","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1016\/j.numecd.2014.05.009_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.fpc.0000114750.08559.32","article-title":"High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)","volume":"14","author":"Niemi","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.numecd.2014.05.009_bib23","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.3390\/ijms12095815","article-title":"Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response","volume":"12","author":"Rodrigues","year":"2011","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2014.05.009_bib24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s10038-006-0025-1","article-title":"Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy","volume":"51","author":"Takane","year":"2006","journal-title":"J Hum Genet"},{"key":"10.1016\/j.numecd.2014.05.009_bib25","doi-asserted-by":"crossref","first-page":"e1003058","DOI":"10.1371\/journal.pgen.1003058","article-title":"RHOA is a modulator of the cholesterol-lowering effects of statin","volume":"8","author":"Medina","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.numecd.2014.05.009_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2265.2007.03144.x","article-title":"Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men","volume":"69","author":"Chan","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.numecd.2014.05.009_bib27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1194\/jlr.P001172","article-title":"Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly","volume":"51","author":"Polisecki","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib28","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1194\/jlr.M026054","article-title":"The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin","volume":"53","author":"Hu","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.atherosclerosis.2004.12.019","article-title":"A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin","volume":"180","author":"Kajinami","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2014.05.009_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0021-9150(94)05439-P","article-title":"Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy","volume":"113","author":"Ordovas","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2014.05.009_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/dmdi.2011.107","article-title":"Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events","volume":"26","author":"Hubacek","year":"2011","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.numecd.2014.05.009_bib32","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1194\/jlr.P021113","article-title":"Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)","volume":"53","author":"Deshmukh","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib33","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2014.05.009_bib34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.numecd.2014.05.009_bib35","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1098-2825(2000)14:3<125::AID-JCLA7>3.0.CO;2-S","article-title":"Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia","volume":"14","author":"Salazar","year":"2000","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.numecd.2014.05.009_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.numecd.2014.05.009_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01213011-200504000-00005","article-title":"Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia","volume":"15","author":"Miltiadous","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.numecd.2014.05.009_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FPC.0b013e3283642fd6","volume":"23","author":"Donnelly","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.numecd.2014.05.009_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0021-9150(94)90065-5","article-title":"Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers","volume":"110","author":"Hannuksela","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2014.05.009_bib41","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/01.CIR.0000153341.46271.40","article-title":"Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects","volume":"111","author":"Boekholdt","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2014.05.009_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/tpj.2010.11","article-title":"Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study","volume":"11","author":"de Keyser","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.numecd.2014.05.009_bib43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2337\/dc09-1724","article-title":"Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects","volume":"33","author":"Takahashi","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.numecd.2014.05.009_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.33549\/physiolres.932341","article-title":"Impact of variants within seven candidate genes on statin treatment efficacy","volume":"61","author":"Vrabl\u00edk","year":"2012","journal-title":"Physiol Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","article-title":"Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study","volume":"34","author":"Hopewell","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2014.05.009_bib46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/tpj.2012.12","article-title":"Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial","volume":"13","author":"van der Baan","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.numecd.2014.05.009_bib47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","article-title":"Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the cholesterol and pharmacogenetics (CAP) Study","volume":"97","author":"Simon","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/ATVBAHA.113.301301","article-title":"Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation","volume":"34","author":"Y1","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2014.05.009_bib49","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/QAD.0b013e32801120e3","article-title":"Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy","volume":"20","author":"Boccara","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.numecd.2014.05.009_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-511X-6-27","article-title":"Are HIV positive patients resistant to statin therapy?","volume":"6","author":"Johns","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2014.05.009_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.08.2011.4620","article-title":"Statin resistant dyslipidemia in a patient treated with amiodarone","author":"Al-Sarraf","year":"2011","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.numecd.2014.05.009_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11306-010-0207-x","article-title":"Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study","volume":"6","author":"Kaddurah-Daouk","year":"2010","journal-title":"Metabolomics"},{"key":"10.1016\/j.numecd.2014.05.009_bib53","doi-asserted-by":"crossref","first-page":"e38386","DOI":"10.1371\/journal.pone.0038386","article-title":"Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment","volume":"7","author":"Trupp","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2014.05.009_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d12","article-title":"Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data","volume":"342","author":"Bell","year":"2011","journal-title":"Br Med J"},{"key":"10.1016\/j.numecd.2014.05.009_bib55","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.numecd.2014.05.009_bib56","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1345\/aph.1P150","article-title":"Predictors of nonadherence to statins: a systematic review and meta-analysis","volume":"44","author":"Mann","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.numecd.2014.05.009_bib57","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jacl.2010.08.026","article-title":"The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review","volume":"4","author":"Simpson","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2014.05.009_bib58","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ypmed.2010.09.015","article-title":"Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey","volume":"51","author":"Reiner \u017d","year":"2010","journal-title":"Prev Med"},{"key":"10.1016\/j.numecd.2014.05.009_bib59","first-page":"944","article-title":"Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service","volume":"46","author":"Bergman Markovi\u0107","year":"2005","journal-title":"Croat Med J"},{"key":"10.1016\/j.numecd.2014.05.009_bib60","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.atherosclerosis.2010.09.014","article-title":"Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey","volume":"213","author":"Reiner","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2014.05.009_bib61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3325\/cmj.2012.53.278","article-title":"The perception and knowledge of cardiovascular risk factors among medical students","volume":"53","author":"Reiner","year":"2012","journal-title":"Croat Med J"},{"key":"10.1016\/j.numecd.2014.05.009_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the cleveland clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2014.05.009_bib63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.numecd.2014.05.009_bib64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.numecd.2014.05.009_bib65","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","article-title":"Weighing the benefits of high-dose simvastatin against the risk of myopathy","volume":"365","author":"Egan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2014.05.009_bib66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib67","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1185\/03007995.2012.702102","article-title":"Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D","volume":"28","author":"Riphagen","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.numecd.2014.05.009_bib68","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/hep.22402","article-title":"Statins in liver disease: a molehill, an iceberg, or neither?","volume":"48","author":"Argo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2014.05.009_bib69","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.arcmed.2013.12.003","article-title":"Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease","volume":"45","author":"Oni","year":"2014","journal-title":"Arch Med Res"},{"key":"10.1016\/j.numecd.2014.05.009_bib70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1665-2681(19)30908-1","article-title":"Statin use is not associated with liver related mortality","volume":"13","author":"Younoszai","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.numecd.2014.05.009_bib71","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib72","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrcardio.2013.117","article-title":"Pharmacotherapies for lipid modification: beyond the statins","volume":"10","author":"Gotto","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib73","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.numecd.2013.05.002","article-title":"Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update","volume":"23","author":"Reiner","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2014.05.009_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1472-8206.2009.00764.x","article-title":"Combined therapy in the treatment of dyslipidemia","volume":"24","author":"Reiner","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.numecd.2014.05.009_bib75","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1185\/030079905X28872","article-title":"Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias","volume":"21","author":"Wierzbicki","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.numecd.2014.05.009_bib76","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.amjcard.2004.06.008","article-title":"Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia","volume":"94","author":"Xydakis","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib77","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1210\/jc.2009-1952","article-title":"Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin","volume":"95","author":"Lakoski","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2014.05.009_bib78","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7326\/0003-4819-150-12-200906160-00006","article-title":"Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial","volume":"150","author":"Becker","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2014.05.009_bib79","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2014.05.009_bib80","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2014.05.009_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2014.05.009_bib82","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2014.05.009_bib83","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475314001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475314001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T13:17:23Z","timestamp":1597929443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475314001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0939475314001732"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2014.05.009","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance and intolerance to statins","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2014.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}